Author: Park, Ji-Young; Yuk, Heung Joo; Ryu, Hyung Won; Lim, Su Hwan; Kim, Kyung Su; Park, Ki Hun; Ryu, Young Bae; Lee, Woo Song
Title: Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors Cord-id: oz2ztmzo Document date: 2017_1_22
ID: oz2ztmzo
Snippet: The current study was designed to assess the inhibitory activity of Broussonetia papyrifera-derived polyphenols against 3-chymotrypsin-like and papain-like coronavirus cysteine proteases. The isolated compounds were broussochalcone B (1), broussochalcone A (2), 4-hydroxyisolonchocarpin (3), papyriflavonol A (4), 3′-(3-methylbut-2-enyl)-3′,4,7-trihydroxyflavane (5), kazinol A (6), kazinol B (7), broussoflavan A (8), kazinol F (9), and kazinol J (10). All polyphenols were more potent against p
Document: The current study was designed to assess the inhibitory activity of Broussonetia papyrifera-derived polyphenols against 3-chymotrypsin-like and papain-like coronavirus cysteine proteases. The isolated compounds were broussochalcone B (1), broussochalcone A (2), 4-hydroxyisolonchocarpin (3), papyriflavonol A (4), 3′-(3-methylbut-2-enyl)-3′,4,7-trihydroxyflavane (5), kazinol A (6), kazinol B (7), broussoflavan A (8), kazinol F (9), and kazinol J (10). All polyphenols were more potent against papain-like protease (PL(pro)) than against 3-chymotripsin-like protease (3CL(pro)); therefore, we investigated their structural features that were responsible for this selectivity. Compound 4 was the most potent inhibitor of PL(pro) with an IC(50) value of 3.7 μM. The active compounds displayed kinetic behaviors, and the binding constants of their interaction with PL(pro) were determined from surface plasmon resonance analysis. Our results suggest B. papyrifera constituents as promising candidates for development into potential anti-coronaviral agents.
Search related documents:
Co phrase search for related documents- accession number and active site: 1
- accession number and acute respiratory syndrome: 1, 2, 3
- acetate buffer and acute respiratory syndrome: 1
- acetate buffer and ma billerica: 1
- acetate buffer and ma billerica millipore: 1
- acetate buffer and magnetic resonance: 1
- active compound and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- active compound and magnetic resonance: 1, 2, 3, 4
- active protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- active protein and magnetic resonance: 1
- active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- active site and low micromolar range: 1, 2, 3, 4, 5, 6
- active site and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9
- activity base and acute respiratory syndrome: 1, 2
Co phrase search for related documents, hyperlinks ordered by date